Ciprofloxacin 3mg/ml / Fluocinolone acetonide 0.25mg/ml ear drops 0.25ml unit dose preservative free
Requires a prescription from a doctor or prescriber
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ciprofloxacin + Fluocinolone acetonide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Cetraxal brand family (generic: Ciprofloxacin + Fluocinolone acetonide)
MHRA licensed products
View all licensed products for Ciprofloxacin + Fluocinolone acetonide on the MHRA register
Cetraxal Plus 3mg/ml + 0.25mg/ml ear drops 0.25ml unit dose
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 2 · 2003–2025
Showing the 50 most relevant studies, sorted by most relevant.
L. F. Christensen, A.-G. Hassing, O. Klefter, et al.
Ocular Immunology and Inflammation, 2024
Weiping Hu, Liyang Ni, Huangfang Ying, et al.
Pakistan Journal of Medical Sciences, 2025
ABSTRACT Background & Objective: Several diabetic macular edema (DME) patients are resistant to anti-vascular endothelial growth factors (VEGF) injections and are treated with corticosteroid implants. Dexamethasone implants (DEXI) are popular, but fluocinolone acetonide implants (FACI) are being used as third-line DME therapy, given their convenience and prolonged action. The efficacy of FACI in patients previously treated with DEXI remains understudied. We collated evidence from single-arm studies examining the efficacy and safety of FACI in DME patients treated with DEXI. Methodology: We explored the websites of Embase, PubMed, PubMed CENTRAL, Web of Science, and Scopus up to January 15, 2025. Pre and post-FACI best-corrected visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) were compared. Results: Eight studies with 365 eyes were included. Meta-analysis showed that use of FACI was associated with statistically significant improvement in BCVA (letters) at three months (MD: 5.40 95% CI: 0.13, 10.67 I2= 78%) but not at six months (MD: 5.43 95% CI: 1.79, 12.64 I2=86%), and 12 months (MD: 3.39 95% CI: 3.12, 9.91 I>2=84%). The pooled analysis indicated a statistically significant reduction in CRT after administration of FACI at 3 months (MD: 118.11 95% CI: 211.62, -24.61 I2=93%), six months (MD: 121.79 95% CI: 212.35, -31.24 I2=94%), and 12 months (MD: 108.33 95% CI: 175.47, -41.2 I2=92%). No significant change in IOP was noted at all follow-up intervals. Conclusions: Use of FACI in patients previously treated with DEXI results in anatomical improvement but may be associated with limited visual gain. The use of FACI seems safe without significant change in IOP. Registration: PROSPERO CRD42025635691.
Abstract licence: CC BY
L. Kodjikian, S. Baillif, C. Creuzot-Garcher, et al.
Pharmaceutics, 2021
Suji Yeo, Yoo-Ri Chung, Ji Hun Song, et al.
Biomedicines, 2025
M. Fallico, A. Maugeri, A. Lotery, et al.
Scientific Reports, 2021
Flávio Ribeiro, M. Falcão
Journal of Ophthalmology, 2021
Honghua Hu, Pengfei Zhou, Hongliang Yao, et al.
Journal of Cosmetic Dermatology, 2025
Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however, the effects of this treatment in the Chinese population remain unclear. Due to the differences between Chinese and Caucasian subjects, further clinical trials in Chinese patients with melasma are needed.
Abstract licence: CC BY
Archives of Ophthalmology, 2008
Uwe Pleyer, C. Pavesio, E. Miserocchi, et al.
Journal of Ophthalmic Inflammation and Infection, 2024
Yusuf Mushtaq, Maryam Mushtaq, Z. Gatzioufas, et al.
Drug Design, Development and Therapy, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.